

A novel pancreatic β -cell isoform of calcium/calmodulin-dependent protein kinase II (β_3 isoform) contains a proline-rich tandem repeat in the association domain

Virginia Urquidí*, Stephen J.H. Ashcroft

Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK

Received 11 November 1994

Abstract There is evidence for a role for calcium/calmodulin-dependent protein phosphorylation in regulation of insulin secretion but the molecular nature of the kinase(s) responsible is unknown. In this study, the screening of a neonatal rat islet cDNA library resulted in the isolation of a 2 kb clone that was 99% homologous to the β' isoform of calcium/calmodulin-dependent protein kinase II. The predicted 589 amino acid sequence with a calculated mass of 64,976 Da contained a 24 amino acid deletion in addition to the 15 amino acid deletion that differentiates the β' from the β isoform, and included an 86 amino acid novel domain consisting of a tandem repeat of proline-rich residues. The expression of this new isoform of calcium/calmodulin-dependent protein kinase II (β_3) was confirmed in β -cell lines and testis by DNA amplification of the sequence encoding the inserted domain by reverse transcriptase-polymerase chain reaction, followed by Southern analysis.

Key words: CaM kinase II; Insulin secretion; Protein phosphorylation; β -cell

1. Introduction

It is well established that insulin secretagogues such as glucose, which lead to an increase in intracellular Ca^{2+} via depolarization of the β -cell, are able to initiate insulin release [1]. There is growing evidence that a calcium/calmodulin-dependent protein kinase (CaM kinase), the activity of which has been detected in association with the cytoskeleton in isolated pancreatic islets [2,3], plays an important role in glucose-regulated insulin secretion. That inhibition of β -cell CaM kinase results in inhibition of insulin release has been demonstrated in pancreatic islets with the use of the diabetogenic agent, alloxan, and its analogue, dehydrouretil [4,5] and at the single cell level with a specific peptide inhibitor of CaM kinase [6]. The activation of islet CaM kinase has been shown to exhibit a close correlation with glucose-induced insulin secretion [7]. It has been suggested that β -cell CaM kinase may be similar or identical to CaM kinase II [8]. This multifunctional protein kinase, although predominantly expressed in neurons, is present in a variety of mammalian tissues and has been implicated in the regulation of multiple cellular processes, including contractility, and neurotransmitter release and synthesis [9,10]. CaM kinase II is a multimer of 4–12 subunits [10,11], each containing

a catalytic, a regulatory and an association domain. The association domain is believed to be required for the assembly of subunits and for specific targeting to subcellular locations. Molecular cloning indicates that at least four distinct genes encode CaM kinase II isoforms, designated as α , β , γ and δ . Alternatively spliced variants of each subunit, which differ in insertions or deletions between the calmodulin binding site in the regulatory domain and the association domain, are expressed in different tissues [11–16], suggesting specific functional roles for each isoform. A sequence inserted in the variable domain of δ_B CaM kinase II appears to be responsible for its nuclear targeting [17]. The γ and δ subunits appear to be the predominant forms in peripheral tissues, and although the α and β/β' isoforms have only been cloned from neural tissues, β -subunit-specific mRNA species have also been detected in skeletal muscle, diaphragm, small intestine and testis [18].

In this study we present conclusive evidence that β -cells express CaM kinase II. We report here the cloning from rat pancreatic islets of a novel isoform of CaM kinase II that we designate as β_3 that appears to be the product of alternative splicing of the β -subunit gene transcript. This is the first time that a β -isoform of CaM kinase II has been cloned from a non-neuronal source.

2. Materials and methods

2.1. Isolation and sequencing of cDNA clones

A neonatal rat islet cDNA library constructed in pCDM8 (InVitrogen) was screened using random-primer ^{32}P -labelled probes corresponding to two contiguous *EcoRI*–*BsaHI* restriction fragments (730 and 815 bp) of a cDNA clone of mouse brain CaM kinase II α -subunit. Eleven putative CaM kinase clones were isolated after three rounds of screening, and subcloned into pBluescript (Stratagene). The 5' and 3' ends of three clones were sequenced by the dideoxynucleotide chain termination method [19] using Sequenase 2.0 (US Biochemicals). Two clones had identical nucleotide composition and the third consisted of an internal fragment that was 100% homologous to the CaM kinase II β -subunit. The sequence of both strands of one of the clones, encompassing the entire CaM kinase II coding region, was determined and compared to DNA sequences of the cloned CaM kinase II isoforms using the University of Wisconsin Genetic Computers Group software package [20].

2.2. Reverse transcription and polymerase chain reaction

Total RNA was purified from rat tissues and β -cell lines [21] and used for reverse transcription-polymerase chain reaction (RT-PCR) [22] with Moloney murine leukemia virus reverse transcriptase (Life Technologies) and the antisense primer complementary to nucleotides 1413–1434 of β_3 CaM kinase II. One twentieth of the volume of the reverse transcription reactions was subjected to amplification with the sense primer, corresponding to nucleotides 1131–1154 of β_3 CaM kinase II and the antisense primer (primer pair I, each primer included *Bam*HI sites and 4 extra nucleotides at their 5' ends). Coding regions of rat brain CaM kinase cloned subunits α and β , and γ , were amplified with the sense

*Corresponding author. Fax: (44) (865) 221 834.

The nucleotide sequence(s) presented here has (have) been submitted to the EMBL/GenBank database under the accession number no. X83375.

Expression of the β -isoform of CaM kinase II has previously been regarded as confined to the nervous system [17]. The β_3 isoform appears to be derived by alternative splicing of the same primary transcript as the β form. Our results with RT-PCR on various tissues suggest that the splicing event giving rise to the β_3 form has a restricted tissue distribution. It should also be noted that although two independent clones isolated from the rat islet cDNA library corresponded to the β -subunit, there is no evidence for that to be the only or even the predominant isoform of the enzyme in the β -cell. It has been shown that the level of β message decreases during neuronal development and that the $\alpha:\beta$ ratio in forebrain increases more than twofold, the β -subunit being the dominant isozyme at birth [10]. These facts may therefore account for a higher probability of isolating clones of the β isoform from the neonatal rat islet library.

Expression of the cloned β_3 isoform and studies on subcellular localization of the enzyme will contribute to the understanding of structure–function relationships.

Acknowledgements: This study has been supported by grants from the Medical Research Council, the British Diabetic Association and the Wellcome Trust. We thank Dr. B. Michelsen, Hagedorn Research Institute, Gentofte, Denmark, for the rat islet cDNA library; Profs. A.R. Means, Duke University, Durham, NC, USA, and H. Fujisawa, Asahikawa Medical College, Japan, for the CaM kinase II cDNA clones; and Profs. J.-I. Miyazaki, University of Tokyo and A.E. Boyd III, Tufts University, Boston, for the β -cell lines MIN6 and HIT T15, respectively.

References

- [1] Ashcroft, S.J.H. and Ashcroft, F.M. (1992) *Insulin: Molecular Biology to Pathology*, pp. 97–150, IRL Press, Oxford.
- [2] Harrison, D.E. and Ashcroft, S.J.H. (1982) *Biochim. Biophys. Acta* 714, 313–319.
- [3] Ashcroft, S.J.H. and Hughes, S.J. (1990) *Biochem. Soc. Trans.* 18, 116–118.
- [4] Colca, J.R., Kotagal, N., Brooks, C.L., Lacy, P.E., Landt, M. and McDaniel, M.L. (1983) *J. Biol. Chem.* 258, 7260–7263.
- [5] Harrison, D.E., Poje, M., Rocic, B. and Ashcroft, S.J.H. (1986) *Biochem. J.* 237, 191–196.
- [6] Ämmälä, C., Eliasson, L., Bokvist, K., Larsson, O., Ashcroft, F.M. and Rorsman, P. (1993) *J. Physiol.* 472, 665–689.
- [7] Wenham, R.M., Landt, M. and Easom, R.A. (1994) *J. Biol. Chem.* 269, 4947–4952.
- [8] Hughes, S.J., Smith, H. and Ashcroft, S.J.H. (1993) *Biochem. J.* 289, 795–800.
- [9] Colbran, R.J. and Soderling, T.R. (1990) *Curr. Topics Cell. Regul.* 31, 181–221.
- [10] Hanson, P.I. and Schulman, H. (1992) *Annu. Rev. Biochem.* 61, 559–601.
- [11] Zhou, Z.L. and Ikebe, M. (1994) *Biochem. J.* 299, 489–495.
- [12] Bulleit, R.F., Bennett, M.K., Molloy, S.S., Hurley, J.B. and Kennedy, M.B. (1988) *Neuron* 21, 63–72.
- [13] Nghiem, P., Saati, S.M., Martens, C.L., Gardner, P. and Schulman, H. (1993) *J. Biol. Chem.* 268, 5471–5479.
- [14] Schworer, C.M., Rothblum, L.I., Thekkumkara, T.J. and Singer, H.A. (1993) *J. Biol. Chem.* 268, 14443–14449.
- [15] Edman, C.F. and Schulman, H. (1994) *Biochim. Biophys. Acta* 1221, 89–101.
- [16] Mayer, P., Möhlig, M., Schatz, H. and Pfeiffer, A. (1994) *Biochem. J.* 298, 757–758.
- [17] Srinivasan, M., Edman, C.F. and Schulman, H. (1994) *J. Cell Biol.* 126, 839–852.
- [18] Tobimatsu, T. and Fujisawa, H. (1989) *J. Biol. Chem.* 264, 17907–17912.
- [19] Sanger, G., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463–5467.
- [20] Devereux, J., Haeblerli, P. and Smithies, O. (1984) *Nucleic Acids Res.* 12, 387–395.
- [21] Chirgwin, J.J., Przbyla, A.E., Mac Donald, R.J. and Rutter, W.J. (1979) *Biochemistry* 18, 5294–5299.
- [22] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbour Laboratory Press, New York.
- [23] Smith, T.F. and Waterman, M.S. (1981) *J. Mol. Biol.* 147, 195–197.
- [24] Altschul, S.F., Gish, W., Miller, W., Myers, E.W. and Lipman, D.J. (1990) *J. Mol. Biol.* 215, 403–410.
- [25] Gout, I., Dhand, R., Hiles, I.D., Fry, M.J., Panayotou, G., Das, P., Truong, O., Totty, N.F., Hsuan, J., Booker, G.W., Campbell, I.D. and Waterfield, M.D. (1993) *Cell* 75, 25–36.
- [26] Gallo, K.A., Mark, M.R., Scadden, D.T., Wang, Z., Gu, Q. and Godowski, P.J. (1994) *J. Biol. Chem.* 269, 15092–15100.
- [27] Wenham, R.M., Landt, M., Walters, S.M., Hidaka, H. and Easom, R.A. (1992) *Biochem. Biophys. Res. Commun.* 189, 128–133.
- [28] Niki, I., Okazaki, K., Saitoh, M., Niki, A., Niki, H., Tamagawa, T., Iguchi, A. and Hidaka, H. (1993) *Biochem. Biophys. Res. Commun.* 191, 255–261.
- [29] Williamson, M.P. (1994) *Biochem. J.* 297, 249–260.
- [30] Schiebler, W., Jahn, R., Doucet, J.-P., Rothlein, J. and Greengard, P. (1986) *J. Biol. Chem.* 261, 8383–8390.
- [31] Nichols, R.A., Sihra, T.S., Czernik, A.J., Nairn, A.C. and Greengard, P. (1990) *Nature* 343, 647–651.
- [32] Llinás, R., Mc Guinness, T.L., Leonard, C.S., Sugimori, M. and Greengard, P. (1985) *Proc. Natl. Acad. Sci. USA* 82, 3035–3039.
- [33] Benfenati, F., Valtorta, F., Rubenstein, J.L., Gorelick, F.S., Greengard, P. and Czernik, A.J. (1992) *Nature* 359, 417–420.
- [34] Hubbard, M.J. and Cohen, P. (1993) *Trends Biochem. Sci.* 18, 172–177.